Drug maker tracks Real-World results of breast cancer medication
NCT ID NCT04982848
Summary
This study aims to observe how the breast cancer drug Talzenna performs in real-world clinical practice in Korea after its approval. It will follow 600 patients already scheduled to receive Talzenna to monitor its safety and effectiveness. This is an observational study, meaning researchers will collect data from standard patient care without changing treatment plans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.